Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 1/20 | 0.33 |
| ▸ | OXTR | P30559 | 1/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4881588 | 0.92 | MAPK1 (0.33) | AVPR2OXTRAVPR1AHSP90AB1USP2 | |
| SCHEMBL4884416 | 0.85 | USP2 (0.35) | AVPR2OXTRAVPR1AUSP2CYP1A2 | |
| SCHEMBL4887345 | 0.82 | TIPARP (0.36) | OXTRAVPR1AHSP90AB1USP2CYP1A2 | |
| SCHEMBL4619490 | 0.81 | TRPA1 (0.39) | OXTRAVPR1AUSP2CYP1A2CYP3A4 | |
| SCHEMBL4740390 | 0.81 | TRPA1 (0.30) | AVPR2OXTRAVPR1ATRPA1TRPM8 | |
| SCHEMBL4882039 | 0.78 | USP2 (0.33) | AVPR1AHSP90AB1USP2CYP1A2CYP3A4 | |
| SCHEMBL4619486 | 0.76 | PDK2 (0.32) | AVPR1AUSP2TRPA1TRPM8 | |
| SCHEMBL4685446 | 0.75 | DRD2 (0.35) | AVPR1AUSP2TRPA1TRPM8KCNH2 | |
| SCHEMBL4624366 | 0.74 | TRPA1 (0.34) | AVPR1AUSP2CYP1A2CYP3A4TRPA1 | |
| SCHEMBL4621202 | 0.74 | PDK2 (0.31) | USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234252-A1 | Compounds Useful in Therapy | PFIZER INC | 2008-09-25 | — | — | US | claimed |
| US-20080234252-A1 | Compounds Useful in Therapy | PFIZER INC | 2008-09-25 | — | — | US | disclosed |
| US-20080234252-A1 | Compounds Useful in Therapy | PFIZER INC | 2008-09-25 | — | — | US | disclosed |
| US-20080234252-A1 | Compounds Useful in Therapy | PFIZER INC | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234252-A1 | Compounds Useful in Therapy | AVPR1A, AVPR1B, AVPR2 | AVPR2 3/4885OXTR 11/4885AVPR1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.